CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 49 filers reported holding CORVUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $363,394 | -11.2% | 248,900 | +39.2% | 0.00% | 0.0% |
| Q2 2023 | $409,452 | +140.2% | 178,800 | -4.5% | 0.00% | – |
| Q1 2023 | $170,443 | -23.0% | 187,300 | -28.0% | 0.00% | -100.0% |
| Q4 2022 | $221,255 | -43.7% | 260,300 | -45.8% | 0.00% | 0.0% |
| Q3 2022 | $393,000 | +6.2% | 480,100 | +28.6% | 0.00% | 0.0% |
| Q2 2022 | $370,000 | -45.9% | 373,400 | -10.5% | 0.00% | -50.0% |
| Q1 2022 | $684,000 | -62.8% | 417,200 | -45.3% | 0.00% | -60.0% |
| Q4 2021 | $1,840,000 | +139.0% | 763,400 | +164.8% | 0.01% | +150.0% |
| Q2 2021 | $770,000 | -14.3% | 288,300 | -1.3% | 0.00% | 0.0% |
| Q1 2021 | $899,000 | +799.0% | 292,000 | +691.8% | 0.00% | – |
| Q2 2020 | $100,000 | +63.9% | 36,880 | +27.7% | 0.00% | – |
| Q1 2020 | $61,000 | -32.2% | 28,880 | +74.2% | 0.00% | – |
| Q4 2019 | $90,000 | – | 16,580 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 3,749,379 | $18,147,000 | 3.77% |
| VR Adviser, LLC | 3,427,461 | $16,589,000 | 2.13% |
| ADAMS STREET PARTNERS LLC | 3,275,616 | $15,854,000 | 2.04% |
| Telemetry Investments, L.L.C. | 196,168 | $949,000 | 1.28% |
| DC Investments Management, LLC | 50,709 | $245,000 | 0.46% |
| Orbimed Advisors | 6,943,654 | $33,607,000 | 0.37% |
| EcoR1 Capital, LLC | 2,081,077 | $10,072,000 | 0.35% |
| BVF INC/IL | 1,370,947 | $6,635,000 | 0.26% |
| Ikarian Capital, LLC | 757,545 | $3,666,000 | 0.26% |
| CHI Advisors LLC | 165,927 | $803,000 | 0.23% |